ISPE Previews Drug Shortages Prevention Plan - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ISPE Previews Drug Shortages Prevention Plan


ISPE announced on Aug. 27 that it released a preview of its Drug Shortages Prevention Plan, developed by ISPE’s Drug Shortages Task Team, aimed at helping the pharmaceutical industry avoid drug shortages, identify root causes, create and sustain organizational cultures, and maintain a robust and reliable supply of medications to patients world-wide. The Introductory Summary to the Plan released on Aug. 27 provides a first look at what is covered in the complete Plan.

“Our goal is that the pharmaceutical industry will use the Plan not only to help them look holistically across the supply chain, but also as a roadmap to use in challenging their current processes, systems and practices and to identify potential gaps and risks,” said ISPE CEO and president, Nancy Berg.

According to Berg, ISPE’s 2013 study on drug shortages provided clear evidence that mitigating shortages requires a holistic approach that includes careful alignment of organizational aspects, people, as well as the technical aspects of process and production in understanding risks and signals indicating a drug shortage may be possible.

The ISPE Drug Shortages Task Team will release the complete Drug Shortages Prevention Plan during the 2014 ISPE Annual Meeting that will be held Oct. 12-15 in Las Vegas, Nevada, US.

Read more about the full report here.

Source: ISPE

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here